While evidence suggests that inhibiting AR activity could block tumor progression, AR signaling also plays a key role in regulating BCa resistance to conventional therapies, making it necessary to combine AR-targeted treatments with other approaches, such as immune checkpoint inhibitors, to improve therapeutic outcomes [136]. Here, AR is linked to neoplasm.